公开(公告)号：US20170218017A1

公开(公告)日：2017-08-03

申请号：US15263028

申请日：2016-09-12

申请人： H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. ,  INTEZYNE TECHNOLOGIES INC. ,  ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA ,  BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM

发明人： ROBERT J. GILLIES ,  DAVID L. MORSE ,  NATALIE M. BARKEY ,  KEVIN N. SILL ,  JOSEF VAGNER ,  NARGES K. TAFRESHI ,  JONATHAN L. SESSLER ,  CHRISTIAN PREIHS ,  VICTOR J. HRUBY

IPC分类号： C07K5/117 ,  C07K7/08 ,  A61K49/18 ,  C07K7/06

CPC分类号： C07K5/1024 ,  A61K38/34 ,  A61K47/64 ,  A61K47/6907 ,  A61K49/0056 ,  A61K49/101 ,  A61K49/1809 ,  C07K7/08 ,  C07K14/68 ,  C07K14/723

摘要： The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.

公开(公告)号：US20230167154A1

公开(公告)日：2023-06-01

申请号：US17582368

申请日：2022-01-24

申请人： H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. ,  INTEZYNE TECHNOLOGIES INC. ,  ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA ,  BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM

发明人： ROBERT J. GILLIES ,  DAVID L. MORSE ,  NATALIE M. BARKEY ,  KEVIN N. SILL ,  JOSEF VAGNER ,  NARGES K. TAFRESHI ,  JONATHAN L. SESSLER ,  CHRISTIAN PREIHS ,  VICTOR J. HRUBY

IPC分类号： C07K5/117 ,  A61K49/10 ,  C07K14/72 ,  A61K47/64 ,  A61K47/69 ,  C07K14/68 ,  A61K49/00 ,  A61K49/18 ,  C07K7/08

CPC分类号： C07K5/1024 ,  A61K49/101 ,  C07K14/723 ,  A61K47/64 ,  A61K47/6907 ,  C07K14/68 ,  A61K49/0056 ,  A61K49/1809 ,  C07K7/08 ,  A61K38/34

摘要： The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.

公开(公告)号：US20200002376A1

公开(公告)日：2020-01-02

申请号：US16450382

申请日：2019-06-24

申请人： H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. ,  INTEZYNE TECHNOLOGIES INC. ,  ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA ,  BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM

发明人： ROBERT J. GILLIES ,  DAVID L. MORSE ,  NATALIE M. BARKEY ,  KEVIN N. SILL ,  JOSEF VAGNER ,  NARGES K. TAFRESHI ,  JONATHAN L. SESSLER ,  CHRISTIAN PREIHS ,  VICTOR J. HRUBY

IPC分类号： C07K5/117 ,  A61K49/10 ,  C07K14/72 ,  A61K47/64 ,  A61K47/69 ,  C07K14/68 ,  A61K49/00 ,  A61K49/18 ,  C07K7/08

摘要： The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.